TCW Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.77M Buy
27,059
+699
+3% +$97.9K 0.03% 214
2025
Q4
$3.24M Buy
+26,360
New +$3.2M 0.02% 225
2025
Q3
Sell
-25,794
Closed -$2.86M 288
2025
Q2
$2.86M Buy
25,794
+393
+2% +$41.8K 0.02% 229
2025
Q1
$2.85M Sell
25,401
-4,876
-16% -$503K 0.03% 221
2024
Q4
$2.8M Buy
30,277
+343
+1% +$30.9K 0.02% 231
2024
Q3
$2.51M Sell
29,934
-148,669
-83% -$11.3M 0.02% 239
2024
Q2
$12.3M Sell
178,603
-381,108
-68% -$25.4M 0.11% 120
2024
Q1
$41M Buy
559,711
+4,578
+0.8% +$352K 0.42% 59
2023
Q4
$45M Buy
555,133
+2,852
+0.5% +$222K 0.5% 57
2023
Q3
$41.4M Sell
552,281
-132,753
-19% -$10.2M 0.52% 55
2023
Q2
$52.8M Buy
685,034
+79,757
+13% +$6.36M 0.59% 51
2023
Q1
$50.2M Buy
605,277
+25,873
+4% +$2.14M 0.64% 49
2022
Q4
$49.7M Buy
579,404
+10,298
+2% +$816K 0.71% 46
2022
Q3
$35.1M Buy
569,106
+66,089
+13% +$4.17M 0.51% 54
2022
Q2
$31.1M Sell
503,017
-122,282
-20% -$7.57M 0.41% 64
2022
Q1
$37.2M Sell
625,299
-73,846
-11% -$4.72M 0.35% 76
2021
Q4
$50.8M Buy
699,145
+25,768
+4% +$1.77M 0.42% 63
2021
Q3
$47K Sell
673,377
-6,725
-1% -$472K 0.12% 63
2021
Q2
$46.8M Sell
680,102
-47,332
-7% -$3.16M 0.41% 60
2021
Q1
$47M Sell
727,434
-44,829
-6% -$2.89M 0.45% 61
2020
Q4
$45M Sell
772,263
-47,824
-6% -$2.89M 0.39% 62
2020
Q3
$51.8M Sell
820,087
-6,350
-0.8% -$440K 0.57% 46
2020
Q2
$63.6M Sell
826,437
-122,749
-13% -$9.41M 0.74% 35
2020
Q1
$71M Sell
949,186
-119,504
-11% -$8.26M 0.98% 30
2019
Q4
$69.4M Sell
1,068,690
-90,371
-8% -$5.89M 0.77% 41
2019
Q3
$73.5M Sell
1,159,061
-144,140
-11% -$9.42M 0.84% 41
2019
Q2
$88M Sell
1,303,201
-537,453
-29% -$35.4M 0.94% 36
2019
Q1
$120M Sell
1,840,654
-98,326
-5% -$6.54M 1.15% 26
2018
Q4
$121M Sell
1,938,980
-118,409
-6% -$8.28M 1.25% 22
2018
Q3
$159M Sell
2,057,389
-268,717
-12% -$20.3M 1.3% 22
2018
Q2
$165M Sell
2,326,106
-13,888
-0.6% -$981K 1.34% 18
2018
Q1
$176M Buy
2,339,994
+67,019
+3% +$5.33M 1.43% 14
2017
Q4
$163M Sell
2,272,975
-87,543
-4% -$6.65M 1.31% 22
2017
Q3
$191M Buy
2,360,518
+262,162
+12% +$20M 1.52% 16
2017
Q2
$149M Buy
2,098,356
+85,448
+4% +$5.69M 1.23% 28
2017
Q1
$137M Sell
2,012,908
-169,017
-8% -$11.9M 1.14% 31
2016
Q4
$156M Buy
2,181,925
+518,111
+31% +$38.5M 1.18% 25
2016
Q3
$132M Buy
1,663,814
+216,967
+15% +$17.6M 1% 36
2016
Q2
$121M Buy
1,446,847
+187,430
+15% +$16.6M 0.91% 43
2016
Q1
$116M Buy
1,259,417
+262,335
+26% +$23.7M 0.85% 51
2015
Q4
$101M Buy
997,082
+14,274
+1% +$1.49M 0.72% 54
2015
Q3
$96.5M Buy
982,808
+237,083
+32% +$26.3M 0.69% 58
2015
Q2
$87.3M Buy
745,725
+312,954
+72% +$34.2M 0.56% 69
2015
Q1
$42.5M Buy
432,771
+10,521
+2% +$1.07M 0.2% 118
2014
Q4
$39.8M Sell
422,250
-318,250
-43% -$32.9M 0.17% 122
2014
Q3
$78.8M Sell
740,500
-28,850
-4% -$2.82M 0.32% 90
2014
Q2
$63.8M Buy
769,350
+5,050
+0.7% +$393K 0.26% 93
2014
Q1
$54.2M Buy
764,300
+6,150
+0.8% +$482K 0.22% 98
2013
Q4
$57M Buy
758,150
+2,350
+0.3% +$164K 0.24% 97
2013
Q3
$47.5M Buy
755,800
+7,796
+1% +$466K 0.22% 100
2013
Q2
$38.3M Buy
+748,004
New +$39M 0.19% 106

Other funds holding GILD

TCW Group's GILD Position: Q1 2026 in Review

TCW Group increased its Gilead Sciences (GILD) stake by 2.7% in Q1 2026, buying an estimated $97.9K and bringing the position to 27,059 shares worth $3.77M. The position accounts for 0.03% of the portfolio, ranked #214.

TCW Group first reported a position in GILD in Q2 2013 and has held it in 51 quarters since. The position peaked at $191M in Q3 2017. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • TCW Group held 27,059 shares of Gilead Sciences worth $3.77M as of Q1 2026.
  • TCW Group bought 699 Gilead Sciences shares in Q1 2026, an estimated $97.9K.
  • Gilead Sciences made up 0.03% of TCW Group's portfolio in Q1 2026, its #214 holding.
  • TCW Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 51 quarters since.
  • TCW Group's Gilead Sciences position peaked at $191M in Q3 2017.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on TCW Group's 13F filing for Q1 2026, filed 14 May 2026.